Indeed, they showed that NK cell receptor NKP46 expression by NK cells seems diminished in patient bearing metastatic melanoma, and that chemotherapy could increase expression of NKP46 by NK cells, but IFNγ secretion and degranulation are decreased after chemotherapy in ex-vivo assays, due to up-regulation of inhibiting factor NKG2A [28], [29]. The gene discussed is KLRC1; the disease is metastatic melanoma.